Therapeutic Cancer Vaccination With a Peptide Derived From the Calreticulin Exon 9 Mutations Induces Strong Cellular Immune Responses in Patients With CALR-Mutant Chronic Myeloproliferative Neoplasms

BACKGROUND: The calreticulin (CALR) exon 9 mutations that are identified in 20% of patients with Philadelphia chromosome negative chronic myeloproliferative neoplasms (MPN) generate immunogenic antigens. Thus, therapeutic cancer vaccination against mutant CALR could be a new treatment modality in CA...

Descripción completa

Detalles Bibliográficos
Autores principales: Handlos Grauslund, Jacob, Holmström, Morten Orebo, Jørgensen, Nicolai Grønne, Klausen, Uffe, Weis-Banke, Stine Emilie, El Fassi, Daniel, Schöllkopf, Claudia, Clausen, Mette Borg, Gjerdrum, Lise Mette Rahbek, Breinholt, Marie Fredslund, Kjeldsen, Julie Westerlin, Hansen, Morten, Koschmieder, Steffen, Chatain, Nicolas, Novotny, Guy Wayne, Petersen, Jesper, Kjær, Lasse, Skov, Vibe, Met, Özcan, Svane, Inge Marie, Hasselbalch, Hans Carl, Andersen, Mads Hald
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7952976/
https://www.ncbi.nlm.nih.gov/pubmed/33718228
http://dx.doi.org/10.3389/fonc.2021.637420

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7952976/
https://www.ncbi.nlm.nih.gov/pubmed/33718228
http://dx.doi.org/10.3389/fonc.2021.637420

Ejemplares similares